Revenue from Contracts with Customers (Tables)

12 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue by significant business line

The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the fiscal years ended September 30, 2023, 2022 and 2021 (in thousands):

		2023	2022		2021
Significant Business Line
Life Sciences Products, excluding B Medical	$	192,061	$	199,230	$	199,606
B Medical		113,122		-		-
Sample Repository Solutions		111,593		105,331		88,922
Genomic Services		248,296		250,937		225,175
Total revenue	$	665,072	$	555,498	$	513,703

Schedule of remaining performance obligations

Remaining Performance Obligations. Remaining performance obligations represent the transaction price of unsatisfied or partially satisfied performance obligations within contracts with an original expected contract term that is greater than one year and for which fulfillment of the contract has started as of the end of the reporting period. The aggregate amount of transaction consideration allocated to remaining performance obligations as of September 30, 2023 was $78.4 million. The following table summarizes when the Company expects to recognize the remaining performance

obligations as revenue, the Company will recognize revenue associated with these performance obligations as transfer of control occurs (in thousands):

	As of September 30, 2023
	Less than 1 Year		Greater than 1 Year		Total
Remaining performance obligations	$	54,159	$	24,228	$	78,387